

Patients in the re-excision group were older than the group who underwent no re-excision. Smaller breast size, lobular histology, multifocality, presence of ductal carcinoma in situ (DCIS) component, concomitant cavity shave, and presence of ≥ 2 co-morbidities were factors significantly associated with re-excision. In Multivariate analysis, lobular histology, multifocality, and presence of DCIS component were independently associated with high re-excision rates.

In our experience, re-excision rates were not significantly related to tumour size or location. Our mastectomy rate of 12.8% following initial BCS was higher than the national rate of 7.7%. This was significantly associated with multiple positive margins and multifocality.

Conclusion: We have identified factors that potentially influence re-excision rates following BCS for breast malignancy. These may help to identify breast cancer patients that may benefit from larger initial resections. Furthermore, these factors should be carefully considered when counselling breast cancer patients, and when formulating their management plans, to minimise frequency of re-excision procedures.

49. METASTATIC INVOLVEMENT OF THE OMENTUM IN PATIENTS UNDERGOING OESOPHAGECTOMY: A MULTI-CENTRE STUDY

Rory Brittain¹, Alan Askari¹, Michael Talbot², Amjid Riaz¹. ¹ Watford General Hospital, Watford, UK; ² St George Hospital, Sydney, Australia

Background: There is currently little evidence to implicate the omentum in metastatic spread of oesophageal carcinoma. Routine excision of the omentum may not be justified in the absence of evidence of oncological benefit. This study aimed to characterise tumour involvement of the omentum in oesophageal carcinoma patients undergoing oesophagectomy with curative intent.

Methods: Histology reports were reviewed for 113 patients who underwent oesophagectomy with curative intent at two centres (Watford General Hospital, Hertfordshire, UK; St George Hospital, Sydney, Australia) between 2007 and 2017. Tumour type, stage and lymph node status for each patient was recorded. Each excised omentum was assessed by an experienced pathologist for tumour involvement.

Results: TNM classification was available for 110 cases. Tumour stage was T0 in 12 (10.6%), T1 in 22 (19.7%), T2 in 24 (21.2%), T3 in 43 (38%) and T4 in 9 (7.96%) patients. 68 patients (61.8%) had lymph node metastasis. Omentectomy was performed in 87 patients (77%). Of these, 84 resected omenta (97%) were tumour free and only three (3%) showed evidence of tumour involvement. Tumour staging in these cases was T3N3 (2 patients) and T4N3.

Conclusion: The omentum is rarely a site of metastasis in those undergoing oesophagectomy. Routine excision of the omentum during oesophagectomy is therefore unlikely to improve oncological clearance. Further studies are needed to determine if omentectomy confers any benefit to patient outcomes, and which patient or tumour factors might predispose to development of omental metastasis.

51. COLORECTAL CANCER DIAGNOSIS PATHWAY AT KETTERING GENERAL HOSPITAL: A CLINICAL AUDIT

Mohamed Abdellatif, Tariq Alhammali, George Bisheet, Alia Shamardal, Eiad Elmahi, Yahya Salama. Kettering General Hospital, Kettering, UK

Background: More than 300,000 new cancers are diagnosed yearly in the UK. Early diagnosis and treatment are very crucial. The aim of this audit is to check the compliance of Kettering General Hospital with the rapid CRC diagnostic pathway, recommended by NHS England.

Methods: The timescale of diagnostic process for confirmed CRC cases was extracted from Somerset database. The compliance percentages were calculated for the time of first seen, different tests, diagnosis and treatment started. A subgroup analysis was done to compare patients referred straight to test with those referred to clinic.

Results: 64 out of 2125 patients referred through 2 weeks wait pathway in 2018 were confirmed to have CRC. 97% were first assessed within 14 days. 42% had endoscopy within 2 weeks. A 36% compliance for CT abdomen &

pelvis was double that of MRI pelvis (18%). Only 23 (35%) cases were diagnosed within 21 days. This has reflected on the average waiting time for treatment which was 73 days. The straight-to-test approach achieved faster diagnosis compared to clinic referrals ($p=0.017$).

Conclusion: Although the majority of patients were seen within 14 days, there was a significant delay in investigations, diagnosis and treatment. There was better compliance when patients were referred straight-to-test. A one-stop clinic is another suggestion to tackle the delay.

53. STOP TABLET OVER PRESCRIBING IN DAY CASE BREAST CANCER SURGERY - STOP

Samer Mashlab, Jennifer Crewe, Stephanie Jenkins. University Hospitals Plymouth NHS Trust, Plymouth, UK

Background: Breast cancer surgery is mostly day case surgery as it is superficial and post-operative pain, classed as mild to moderate, can be controlled with over the counter analgesia (OTC). Many units have protocols to prescribe a standard multi-modal analgesia (Paracetamol, Non-Steroidal anti-inflammatories (NSAID), Opioid) on discharge. Prescribing OTC medication is costly and in many cases wasteful as patients have their own analgesia at home. Our aim is to assess practice, cost of prescribing OTC analgesia, and to propose a pathway that encourages patient self-supply of analgesia and education on how to best achieve symptomatic relief.

Method: Data from 100 consecutive breast surgery cases were analysed for age, sex, day case surgery, analgesia, and cost of prescription. Discharge summaries were reviewed to assess analgesia prescription. The pharmacy department calculated cost of processing and supplying one prescription of paracetamol, NSAID, and opioid.

Results: Eighty-two (82/100) cases were booked as day case surgery, one remained as an unplanned inpatient for observation and excluded. 80 Females v 1 male with a mean age of 56 years [IQR 47 – 66]. 72.8% (59/81) of day case patients were prescribed OTC analgesia. The cost per prescription per patient was calculated to be £24.15 with a total cost of £1425 for all cases.

Conclusion: Prescribing simple analgesia is costly and wasteful. A pathway encouraging and educating patients to self-supply OTC analgesia will incur savings to the NHS and a better patient experience.

59. LONG TERM OUTCOMES FROM LATISSIMUS DORSI (LD) FLAP BASED BREAST RECONSTRUCTIONS

Soudamini Nayak¹, Shazia Khan¹, Emma MacInnes¹, Haley Hocking¹, Ghulam Wattoo¹, Irene Athanasiou¹, Kadappa Kolar¹, Clare Rogers¹, Olu Olubowale¹, Kathryn Rigby¹, Nazar Kazzazi¹, Lynda Wylde^{2,1}. ¹ Doncaster and Bassetlaw Teaching Hospitals Foundation Trust, Doncaster, UK; ² Sheffield University, Sheffield, UK

The LD flap reconstruction has been the workhorse of breast reconstruction in delayed setting and until the advent of ADMs, was an important technique in immediate reconstructions. The study presents 12 years follow up of a large single Trust series of over 200 cases.

A consecutive series of LD flap reconstructions was derived from theatre logs between 2002 and 2016. Case notes were reviewed for type of surgery, acute and chronic complications. Risk factors for complications were recorded using Charlson co-morbidity index, smoking status, BMI and use of radiotherapy. Statistical analysis using SPSS was performed.

There were 212 LD flap reconstructions; 88 delayed and 120 immediate. Fully autologous surgery was performed in 68 and supplemented with implant in 136. Median follow up is 7 years. Early adverse events included 7 patients readmitted within 30 days of surgery, usually for infection, partial (2) or complete (1) flap necrosis. There were no deaths. Seromas required aspiration at least once in 150 patients (median of 2, range 1-11). There were 24 minor infections and 1 major infection causing implant loss. Further surgeries were required in 119 women, usually symmetrization (80). Median number of further procedures was 2 (range 1-10). Long-term chronic complications were reported in 30 women (such as back or wound pain, chronic seroma, shoulder stiffness).

The majority of women undergoing LD flap reconstruction do well with minor complications and low rate of major complications (flap/ implant loss) but further surgeries are often required for symmetry, as highlighted in UK-GIRFT audit.

60. THE ROLE OF STAGING PETCT PT4B MELANOMA: A 5 YEAR ANALYSIS

Claire Hardie, Ammar Allouni, Paolo Matteucci. *Hull University Teaching Hospitals, Hull, UK*

Aim: In our Trust, patients diagnosed with pT4b cutaneous melanoma are offered PETCT for initial staging as a sensitive way to detect tumour metastasis. We assessed the value of PETCT in these patients in terms of positive findings from the scan and subsequent recurrence and survival.

Methods: A 5 year retrospective analysis of all patients diagnosed histologically with pT4b melanoma who had staging PETCT in a tertiary referral centre was carried out. Patients were identified using MDT records and cross-referenced with clinical coding. Patient demographics, final staging and results of PETCT were collected and recurrence and survival were monitored.

Results: Of the 60 patients identified over a 5 year period, 24 were females and 36 males. The median age was 74 (range 54–86). 13.3 % had metastases identified on staging PETCT. 81.6 % had wide local excision and 31.6 % had sentinel lymph node biopsy. Over a median follow up period of 2.3 years, 58.3% had recurrence of their melanoma and 28.2% had died.

Conclusion: Initial staging with PETCT may not be necessary for all patients with pT4b melanomas. Few patients had positive findings from the scan and it is a significant radiation dose that carries its own risks. Having the PETCT may also be delaying other interventions including wide local excision and sentinel lymph node biopsy. We can use these results to provide information to patients within our trust and development of a national guideline would be beneficial.

65. INVESTIGATING MEN'S PERCEPTIONS ON THE USE OF MULTIPARAMETRIC MRI FOR THE DIAGNOSIS OF PROSTATE CANCER

Joseph Norris¹, Veeru Kasivisvanathan², Hayley Whitaker¹, Alex Kirkham¹, Alex Freeman¹, Maneesh Ghei³, Daniel Kelly⁴, Mark Emberton¹. ¹University College London, London, UK; ²Frimley Health NHS Foundation Trust, London, UK; ³Whittington Health NHS Trust, London, UK; ⁴Cardiff University, Cardiff, UK

Background: Multiparametric MRI (mpMRI) has enabled enhanced risk stratification for men with suspected prostate cancer; however, views of patients experiencing this novel technology have not been explored.

Method: Men with suspected prostate cancer completed questionnaires that explored their views on the mpMRI-directed pathway, compared to traditional systematic transrectal biopsy. They were also asked about their perception of "significant" cancer. Statistical comparison was with Fisher's exact test. The Joint Research Office at UCL/UCLH deemed this study to be service evaluation.

Results: 56 men completed the questionnaire. Median age was 64 (38–82). 73% of men rated mpMRI as "very good," compared with 19% for the traditional approach. In the context of negative mpMRI, 75% of men were willing to forgo immediate biopsy; however, 9% still opted for biopsy, regardless of mpMRI status. Older men (over 60-years-old) had significantly lower levels of concern than younger men (under 60-years-old) that mpMRI might miss prostate cancer ($p=0.04$). Concerns that men had regarding missed prostate cancer on mpMRI included "reduced treatment time" and "unclear follow-up." When asked about the most significant cancer features, life expectancy was most highly cited, followed by quality of life, then metastasis.

Conclusion: Men with suspected prostate cancer appear to strongly value the diagnostic accuracy and risk stratification afforded by mpMRI. The majority favour avoidance of biopsy in the context of negative mpMRI and consider life expectancy to be the strongest determinant of clinical significance. This is the first dedicated insight into views held by men experiencing the new mpMRI-led diagnostic pathway.

66. EFFICACY OF INTRA-OPERATIVE PTH MONITORING IN DETERMINING POTENTIAL CURE IN PATIENTS UNDERGOING PARATHYROID SURGERY

Kashuf Khan, Allain Rolli, Claire Ford, Andrew Garnham, Harit Buch. *Royal Wolverhampton Trust, Wolverhampton, UK*

Background: Surgical removal of abnormal parathyroid glands is the only curative treatment for Primary Hyperparathyroidism (PHPT); adenoma being the most common cause. The use of Intra-operative Parathyroid Hormone (iPTH) helps to improve the surgical cure rate in patients with one or more adenomas. There are several variations in the site and timing of collection of samples and in the cut-off used to indicate cure. We use pre-incision, pre-excision and 20 minutes post-excision, 50% drop in PTH as the cut-off and Roche analysers rather than Point of Care Testing (POCT).

Methods: iPTH data was collected prospectively in 82 patients underwent parathyroidectomy at a single institution between 2015–2018. 4 patients whose operation was undertaken by a surgeon unfamiliar with the process were excluded. Aim was to assess the positive & negative predictive value (PPV, NPV) of IOPTH in our centre and the mean time taken to obtain the result.

Results: 69 of the 78 patients were cured & the iPTH results were as follows.

Cured (69)	Not Cured (9)		
>50% Fall	<50% Fall	>50% Fall	<50% Fall
68	1	0	9
PPV: 100%	NPV: 88%		

Average time from sample collection to results was 43 minutes (data from 21 patients). Anecdotally this was only a slightly longer than frozen section (data not yet available)

Conclusions: iPTH is highly accurate in intra-operative prediction of cure of parathyroid surgery. We hypothesize that our high PPV/NPV as compared to the literature is due to the use of laboratory analyser rather than POCT although this does prolong the intra-operative time by a small degree.

67. SURVIVAL AND OUTCOMES AFTER ROBOTIC RECTAL CANCER SURGERY – SINGLE CENTRE EXPERIENCE

Mariam Baig, Adeel Bajwa, Charles Evans. *University Hospital Coventry and Warwickshire, Coventry, UK*

Background: Rectal cancer is increasingly being performed robotically as it facilitates precise surgery in three-dimensional high definition. Oncological outcomes in rectal cancer are related to the quality of pathological specimen. This study investigates oncological outcomes in patients undergoing robotic cancer surgery in an experienced Robotic colorectal unit. **Methods:** Patients' clinical information, disease stage, post-operative course and survival outcomes were recorded prospectively with ethical committee approval.

Result: Between February 2015 and July 2019, 84 patients underwent robotic surgery for rectal cancer. Forty nine patients (58.3%) had T3 disease at presentation (21 with T2, 9 with T1 and 5 with T4 disease) and 15 (18%) received preoperative chemoradiation.

Anterior Resection of Rectum was performed in 57 (68%) patients, whereas 24 (28.5%) underwent Abdominoperineal resection of Rectum. Total mesorectal resection (TME) was performed in 60 patients (71.4%) and 24 patients (28.5%) had transection.

Histopathologically, 83 patients (98%) had R0 resection and 79 (94%) specimens were TME grade 3, (3 TME Grade1 and 2 TME Grade2). Adjuvant chemotherapy was given 31 patients (37%).

No patient developed local recurrence. Ten patients (12%) developed distant recurrence, of which seven patients had solitary metastasis, two patients had multiple visceral metastases, and one patient developed